In short
Clinical trials are studying AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA in blood cancers linked to plasma cells. These trials mainly look at safety and how well the treatment works in patients with newly diagnosed primary plasma cell leukemia or relapsed/refractory multiple myeloma.
Key points
- Clinical trials are studying AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA in two plasma cell cancers: newly diagnosed primary plasma cell leukemia and relapsed/refractory multiple myeloma. One trial is Phase 2 and focuses on safety and early response, while the other is Phase 3 and compares progression-free survival with standard treatment. The target groups are patients with newly diagnosed disease in one study and patients whose multiple myeloma has returned or not responded after prior treatment in the other. The planned enrollment is small in the Phase 2 study and larger in the Phase 3 study. The main outcomes include overall response rate, progression-free survival, and safety events such as cytokine release syndrome and neurological toxicity.
Trial overview
These clinical trials are studying AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA in blood cancers that involve plasma cells. The studies are interventional, which means the research team gives a treatment and then watches what happens.
Two authorised trials were provided: one in newly diagnosed primary plasma cell leukemia and one in relapsed/refractory multiple myeloma. The trials are looking mainly at safety and how well the treatment works.
Who is being studied
The first trial includes people with newly diagnosed primary plasma cell leukemia. This is a rare and serious cancer of plasma cells, and the study is testing the treatment after initial therapy to help induce a response.
The second trial includes people with relapsed/refractory multiple myeloma. In simple words, relapsed means the disease came back, and refractory means it did not respond well to earlier treatment. This study focuses on patients who already had 2 to 4 lines of therapy, meaning they have already received 2 to 4 different treatment regimens.
Trial phases and design
The plasma cell leukemia study is a Phase 2 trial with 25 planned participants. Phase 2 studies usually look for early signs that a treatment may help, while still checking safety carefully.
The multiple myeloma study is a Phase 3 trial with 126 planned participants. Phase 3 studies are larger and compare a new treatment with standard treatment to see which works better.
Main endpoints
An endpoint is the main result a trial measures to see whether the treatment is helping. The first trial has one main efficacy endpoint and one main safety endpoint.
- Overall response rate: the first trial measures how many patients have at least a partial response within the first 3 months after the first infusion. A partial response means the cancer gets smaller or improves, but is not completely gone.
- Cytokine release syndrome and neurological toxicity: the first trial also measures how many patients develop these problems in the first 30 days after treatment. Cytokine release syndrome is a strong immune reaction, and neurological toxicity means problems affecting the brain or nerves.
- Progression-free survival: the second trial measures the time patients live without the disease getting worse. This is the main endpoint in the Phase 3 study.
Trial details
The first trial is titled as a study of a humanized CART directed against BCMA (ARI0002h) in newly diagnosed primary plasma cell leukemia, and its brief summary says it is testing safety and efficacy after initial treatment to induce response. The intervention list includes AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA, along with several other medicines used in the treatment plan listed in the source data.
The second trial compares academically produced CAR T cells with standard treatment in people with multiple myeloma that has returned or did not respond to earlier therapy. Its brief summary says the goal is to compare progression-free survival in patients randomized to the CAR T-cell approach versus current standard of care.
What the trial terms mean for patients
Authorised means the trial has been approved to start. Interventional means patients receive a study treatment rather than only being observed.
Enrollment means the number of people the study plans to include. In these trials, the planned enrollment is 25 in the Phase 2 study and 126 in the Phase 3 study.
Randomized means people are assigned to different study groups by chance. This helps compare treatments in a fair way.